Last week, I was in Paris to meet with one of our Investors, during which time I also had a chance to visit the French Cancer Biotech, Onxeo.
I met with the CEO of Onxeo, Judith Greciet, who was confident about the future of the company.
She moved into the role in 2011 after having spent several years in mid-size Pharma and being a French director of Eisai (Japan).
Onxeo originates from the merger of Paris-based BioAlliance Pharma and Topotarget (Denmark). The company has three small-molecule products: Livatag (phase III trial for Liver cancer), Beleodaq (approved in PTCL 2nd line, successful phase I results in first line just announced) and Validive (Phase II).
You seem to have a robust pipeline. What are the future steps of development?
Following our announce in December, we are working on the Phase III of Beleodaq (Belinostat) in combination with the reference treatment as first line treatment (first treatment,